Clinical Focus ›› 2021, Vol. 36 ›› Issue (6): 574-576.doi: 10.3969/j.issn.1004-583X.2021.06.020
-
Received:2020-11-02Online:2021-06-20Published:2021-07-13
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.06.020
| [1] |
Dyson JK, Webb G, Hirschfield GM, et al. Unmet clinical need in autoimmune liver diseases[J]. J Hepatol, 2015, 62(1):208-218.
doi: 10.1016/j.jhep.2014.09.010 URL |
| [2] |
Ma HD, Wang YH, Chang C, et al. The intestinal microbiota and microenvironment in liver[J]. Autoimmun Rev, 2015, 14(3):183-191.
doi: 10.1016/j.autrev.2014.10.013 URL |
| [3] | 韩美林, 龚振华. 肠道菌群在肝胆疾病中的作用机制[J]. 临床肝胆病杂志, 2017, 33(2):384-388. |
| [4] |
Peng H, Wisse E, Tian Z. Liver natural killer cells: Subsets and roles in liver immunity[J]. Cell Mol Immunol, 2016, 13(3):328-336.
doi: 10.1038/cmi.2015.96 pmid: 26639736 |
| [5] |
Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases[J]. Hepatol Res, 2013, 43(2):139-146.
doi: 10.1111/hepr.2013.43.issue-2 URL |
| [6] |
Wei Y, Zeng B, Chen J, et al. Enterogenous bacterial glycolipids are required for the generation of natural killer T cells mediated liver injury[J]. Sci Rep, 2016, 6:36365.
doi: 10.1038/srep36365 URL |
| [7] |
Fine RL, Manfredo Vieira S, Gilmore MS, et al. Mechanisms and consequences of gut commensal translocation in chronic diseases[J]. Gut Microbes, 2019, 11(2):1-14.
doi: 10.1080/19490976.2019.1613124 URL |
| [8] | Lin R, Zhou L, Zhang J, et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J]. Int J Clin Exp Pathol, 2015, 8(5):5153-5160. |
| [9] |
Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3):569-577.
doi: 10.1136/gutjnl-2018-317836 URL |
| [10] |
Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12):1417-1428.
doi: 10.1111/apt.15754 URL |
| [11] |
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation[J]. Cell, 2014, 157(1):121-141.
doi: 10.1016/j.cell.2014.03.011 URL |
| [12] | Liu Chen Kiow J, Vincent C, Sidani S, et al. High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis[J]. Neurogastroenterol Motil, 2019, 31(11):e13691. |
| [13] |
Lv LX, Fang DQ, Shi D, et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis[J]. Environ Microbiol, 2016, 18(7):2272-2286.
doi: 10.1111/1462-2920.13401 URL |
| [14] |
Gao L, Wang L, Woo E, et al. Clinical management of primary biliary cholangitis-strategies and evolving trends[J]. Clin Rev Allergy Immunol, 2020, 59(2):175-194.
doi: 10.1007/s12016-019-08772-7 URL |
| [15] |
Li Y, Tang R, Leung P, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J]. Autoimmun Rev, 2017, 16(9):885-896.
doi: 10.1016/j.autrev.2017.07.002 URL |
| [16] | 黄春洋, 陈杰, 刘燕敏, 等. 肠道菌群在自身免疫性肝病发生发展及治疗中的作用[J]. 临床肝胆病杂志, 2019, 35(1):205-207. |
| [17] |
Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3):534-541.
doi: 10.1136/gutjnl-2016-313332 URL |
| [18] |
Chung BK, Hirschfield GM. Immunogenetics in primary sclerosing cholangitis[J]. Curr Opinion Gastroenterol, 2017, 33(2):93-98.
doi: 10.1097/MOG.0000000000000336 URL |
| [19] |
Irlès-Depé M, Roullet S, Neau-Cransac M, et al. Impact of pre-existing inflammatory bowel disease on the outcome of liver transplantation for primary sclerosing cholangitis[J]. Liver Transpl, 2020, 26(11):1477-1491.
doi: 10.1002/lt.v26.11 URL |
| [20] | Quraishi MN, Sergeant M, Kay G, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD[J]. Gut, 2017, 66(2):386-388. |
| [21] |
Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65(10):1681-1689.
doi: 10.1136/gutjnl-2015-311004 pmid: 27207975 |
| [22] |
Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls[J]. Gut, 2017, 66(4):611-619.
doi: 10.1136/gutjnl-2015-310500 URL |
| [23] |
Ruhlemann M, Liwinski T, Heinsen FA, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis[J]. Aliment Pharmacol Ther, 2019, 50(5):580-589.
doi: 10.1111/apt.15375 URL |
| [24] |
Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis[J]. Nat Microbiol, 2019, 4(3):492-503.
doi: 10.1038/s41564-018-0333-1 URL |
| [25] |
Liao L, Schneider KM, Galvez E, et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis[J]. Gut, 2019, 68(8):1477-1492.
doi: 10.1136/gutjnl-2018-316670 URL |
| [26] | Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis[J]. Gut, 2019, 69(4):2019-318416. |
| [27] |
Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial[J]. Am J Gastroenterol, 2019, 114(7):1071-1079.
doi: 10.14309/ajg.0000000000000115 pmid: 30730351 |
| [1] | . [J]. Clinical Focus, 2024, 39(2): 177-182. |
| [2] | . [J]. Clinical Focus, 2024, 39(1): 84-87. |
| [3] | Yang Zhibin, Shao Yanfang, Pan Li, Yang Yanxia, Yang Yuxi, Zhao Lihui, Zeng Rongkun, Li Yang, Wang Qiaofeng, Wang Cong, Ma Shiwu. Efficacy of magnesium isoglycyrrhizinate in anti-tuberculosis drug-induced liver injury [J]. Clinical Focus, 2021, 36(11): 972-975. |
| [4] | . [J]. Clinical Focus, 2021, 36(9): 856-860. |
| [5] | . [J]. CLINICAL FOCUS, 2014, 29(2): 202-203. |
| [6] | . [J]. CLINICAL FOCUS, 2013, 28(7): 812-813. |
| [7] | WANG Pu;LIU Jiang-wen;TONG De-feng;CUI Yong. Effects of 15-deoxy-prostaglandin J2 on expression of proliferator-activated receptor γ,tumor necrosis factor-α and interleukin-6 in liver tissue of rats with nonalcoholic fatty liver disease [J]. Clinical Focus, 2013, 28(4): 412-0. |
| [8] | . [J]. Clinical Focus, 2012, 27(22): 1993-1994. |
| [9] | . [J]. Clinical Focus, 2012, 27(18): 1610-1611. |
| [10] | ZHANG Jun-xia;LIU Jun-juan;LI Jia. Clinical characteristics of 42 autoimmune hepatitis patients [J]. Clinical Focus, 2012, 27(12): 1050-1053. |
| [11] | . [J]. Clinical Focus, 2011, 26(24): 2170-2171. |
| [12] | . [J]. CLINICAL FOCUS, 2011, 26(20): 1811-1813. |
| [13] | ZHAO Zhao-xia;YE Li-hong;LU Jian-hua;YANG Li;LIU Yan-chao;LIU Yu-zhen;HOU Jun-liang;DAI Er-hei . Quantification of liver hepatitis B virus covalently closed circular DNA in patients with chronic hepatitia B [J]. CLINICAL FOCUS, 2011, 26(13): 1108-1110. |
| [14] | . [J]. CLINICAL FOCUS, 2010, 25(24): 2174-2174. |
| [15] | . [J]. CLINICAL FOCUS, 2010, 25(23): 2106-2108. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||